<?xml version="1.0" encoding="UTF-8"?>
<p>Hiltonol (PolyI:PolyC, stabilized by poly L-lysine and carboxymethylcellulose—Poly ICLC), was developed by Oncovir, Inc. (USA) [
 <xref ref-type="bibr" rid="CR82">82</xref>]. Poly ICLC is characterized by increased resistance to hydrolysis. It induces IFN synthesis and thus exhibits a modulating effect on the immune system cells, including activation of T-cells, NK cells and DC, synthesis of cytokines (interleukins, TNF-α) and corticosteroids. Being less toxic than existing analogs it can be used in higher doses for the treatment of patients with advanced inoperable cancer [
 <xref ref-type="bibr" rid="CR83">83</xref>]. The ClinicalTrials.gov database contains information about 97 clinical trials of Hiltonol for the treatment of oncological diseases of various localization, influenza, severe acute respiratory syndrome (SARS) and other viral diseases [
 <xref ref-type="bibr" rid="CR76">76</xref>]. Hiltonol is an attractive potential drug for treatment for Ebola haemorrhagic fever [
 <xref ref-type="bibr" rid="CR84">84</xref>].
</p>
